Vijay Pande, formerly a prominent Stanford chemistry professor known for the Folding@home distributed-computing project, transitioned from academia to a leading role at Andreessen Horowitz (a16z), where he managed a healthcare and life sciences practice valued at nearly $4 billion. After departing a16z, Pande co-founded a much smaller venture capital firm, VZVC, with longtime investor Zach Werner. Unlike his previous role, VZVC focuses on a limited number of concentrated investments—approximately five per year—rather than the dozens of bets typical of larger funds. The firm operates without associates and leverages artificial intelligence extensively in its day-to-day activities.

Pande discusses the shift in biology from a “science of discovery” to an “engineering” discipline, driven by advancements in artificial intelligence and machine learning. These technologies enable more precise drug target identification, drug design, and clinical trial optimization, potentially reducing the high failure rates and costs associated with traditional drug development. However, he notes a critical challenge: unlike text data, biological data cannot be easily scraped from the internet, leading to the creation of proprietary, walled-off datasets by individual companies. This fragmentation poses questions about the accessibility and democratization of AI-driven medical advances, though Pande anticipates a trend toward open-source biological foundation models that could broaden impact, similar to the trajectory observed with large language models.

This is a summary. Read the original at techcrunch.com.